Beneficial effects in lowering the serum levels of ALT and GGT and improving insulin sensitivity were proven for 4-week treatment with PX-104 at a dose of 5 mg daily in patients with NAFLD diagnoses without diabetes mellitus. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.